The import of Remdesivir Active Pharmaceutical Ingredients (API), injections and specific inputs have been made import duty free till October 31 amid the ongoing surge in COVID-19 cases in the country.
Taking to Twitter, the ministry of finance on Tuesday shared a notification that said that the central government has exempted Remdesivir Active Pharmaceutical Ingredients, Beta Cyclodextrin (SBEBCD) used in the manufacture of Remdesivir -- subject to the condition that the importer follows the procedure set out in the Customs (Import of Goods at Concessional Rate of Duty) Rules, 2017 -- and Injection Remdesivir from the whole of the duty of customs leviable on their import into India.
Commerce and Industry Minister Piyush Goyal tweeted, "In line with PM Narendra Modi's priority to ensure affordable medical care for COVID-19 patients, imports of Remdesivir API, injection and specific inputs have been made import duty free. This should increase supply and reduce cost thus providing relief to patients."
Amid the shortage of Remdesivir in the wake of a spike in COVID-19 infections in the country, seven major pharmaceutical companies have already reduced the maximum retail price (MRP) of the anti-viral drug.
As per the revised price of major brands of Remdesivir injection 100mg/Vial', Cadila Healthcare Ltd's REMDAC which was earlier available at Rs 2,800, has been reduced to Rs 899.
The price of Syngene International Ltd's RemWin is reduced to Rs 2,450 from Rs 3,950. Dr Reddy's Laboratories Ltd's REDYX will be available at Rs 2,700 instead of Rs 5,400.
Cipla Ltd's CIPREMI will now be available at Rs 3,000 instead of Rs 4,000, Maylan Pharmaceuticals Pvt Ltd's DESREM will be available at Rs 3400 instead of Rs 4,800, Jubilant Generics Ltd's JUBI-R will be available at Rs 3,400 instead of Rs 4,700 and Hetero Healthcare Ltd's COVIFOR will be available at Rs 3,490 instead of Rs 5,400.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU